Secondaries activity in western Europe was buoyant in the first half of 2018, with an estimated $11.4bn's worth of transactions, according to the latest Setter Volume Report.
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Existing management team will lead the company's future growth and development